A Study of Bimagrumab in Participants With HFpEF
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 540 participants.
Also called NCT07920887
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 540 participants
- Sponsor
- Registry
-
NCT07920887 -
2026-527983-34-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Hungary, Italy, Poland
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07920887. Randomized; double masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2029-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Bimagrumab in Participants With HFpEF
- Acronym
- ACTIVATE-HFpEF
- Condition
- Heart Failure, Diastolic
- Condition
- Diastolic Heart Failure
- Condition
- Heart Failure, Normal Ejection Fraction
- Condition
- Heart Failure, Preserved Ejection Fraction
- Intervention (Drug)
- Bimagrumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07920887- Content hash
3f7a83be3dd651aecaf6e4520d692a31e28d51a2b5e11b7d5f6691ad834a5670